Drug Information

Drug General Information
Drug ID
D04ADG
Former ID
DCL001004
Drug Name
SU5416
Synonyms
Semaxanib; Semaxinib; Semaxnib; Semoxind; S 8442; SU 5416; VEGF Receptor 2 Kinase Inhibitor III; InSolution™ SU-5416; TSU-16; Semaxanib (USAN/INN); Methylene]-2H-indol-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one; 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl); 1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one; 3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone; 3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole; 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one; 3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one; 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one; 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one
Drug Type
Small molecular drug
Indication Multiple myeloma; HIV infections [ICD9: 001-139, 042, 203.0; ICD10:B20-B24, C90] Phase 2 [468143], [527804], [537114]
Company
Sugen
Structure
Download
2D MOL

3D MOL
Formula
C15H14N2O
InChI
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChIKey
WUWDLXZGHZSWQZ-WQLSENKSSA-N
CAS Number
CAS 204005-46-9
PubChem Compound ID
5329098
PubChem Substance ID
525180, 8034458, 10318718, 11061325, 12015099, 14847387, 17405666, 24278606, 26759729, 26759733, 39301723, 47207480, 47348964, 47572946, 49674962, 49984916, 50076383, 50107014, 50107015, 50107016, 53778216, 53789746, 56312333, 56312335, 56312337, 56312516, 56312518, 56312520, 56320689, 56322916, 57361292, 74446362, 85789116, 90341564, 91722386, 92303403, 99302833, 103175684, 113911626, 121362026, 121493282, 124750244, 124800944, 124891688, 134339165, 134339435, 134340578, 134341737, 135079569, 135141433
Target and Pathway
Target(s) Aryl hydrocarbon receptor Target Info Modulator [527804]
References
Ref 468143(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
Ref 527804A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 527804A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.